Meeting
2020 ASCO Virtual Scientific Program
Landmark analysis of immunotherapy duration and disease free survival in advanced melanoma patients with a complete response.
Authors
Grayce N. Selig
Department of Medicine, University of Pennsylvania, Philadelphia, PA
Grayce N. Selig , Alexander Chan Chi Huang , Giorgos C. Karakousis , Wei Xu , Cathy Zheng , Mary Carberry , Lydia Giles , Kristin Kreider , Suzanne McGettigan , John Nicholas Lukens , Lynn Mara Schuchter , Ravi K. Amaravadi , Tara C. Mitchell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10054)
DOI
10.1200/JCO.2020.38.15_suppl.10054
Abstract #
10054
Poster Bd #
403
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
First Author: Lauren Julia Brown
Poster
2019 ASCO Annual Meeting
Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.
First Author: Georgina V. Long
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Outcomes of immunotherapy in advanced melanoma in relation to age.
First Author: Krishna Prasad Joshi
Poster
2016 ASCO Annual Meeting
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.
First Author: Adil Daud